AbbVie is asking the U.S. Supreme Court to overrule a lower court’s ruling that the company must turn over records of communications with its lawyers regarding a patent lawsuit it filed against a generic drug maker more than a decade ago.
AbbVie will not be pursued any further by the US government over allegations that it used ‘sham’ litigation to keep competition to its AndroGel testosterone replacement product off the market.
The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel.
AbbVie has had success defending against AndroGel lawsuits in court, but the drugmaker still faces thousands of lawsuits alleging harm from the testosterone drug. Now, the sides have reached a “potential global settlement,” according to a court filing Monday from Judge Matthew Kennelly.
A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.
A U.S. judge on Friday found that pharmaceutical company AbbVie Inc (ABBV.N) used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.